Incannex Healthcare is a drug manufacturers - specialty & generic business based in Australia. Incannex Healthcare shares (IHL) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Incannex Healthcare has a trailing 12-month revenue of around $1 million. If you're looking to buy shares, check out the steps below.
Our top pick for
Low costs
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $0.041 - $0.24 |
|---|---|
| 50-day moving average | $0.0595 |
| 200-day moving average | $0.0988 |
| Target price | N/A |
| PE ratio | 0 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.3 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.041
| 1 week (2023-11-23) | 0.041 |
|---|---|
| 1 month (2023-11-03) | -39.71% |
| 3 months (2023-09-01) | -51.76% |
| 6 months (2023-06-02) | -62.73% |
| 1 year (2022-12-02) | -82.17% |
|---|---|
| 2 years (2021-12-03) | -92.26% |
| 3 years (2020-12-03) | -71.72% |
| 5 years (2018-12-03) | 78.26% |
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $1 million |
| Return on assets TTM | -17.5% |
| Return on equity TTM | -33.3% |
| Profit margin | 0% |
| Book value | 0.053 |
| Market capitalisation | $92 million |
TTM: trailing 12 months
We're not expecting Incannex Healthcare to pay a dividend over the next 12 months.
Incannex Healthcare's shares were split on a 1:20 basis on 29 July 2016. So if you had owned 20 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Incannex Healthcare shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Incannex Healthcare shares which in turn could have impacted Incannex Healthcare's share price.
Over the last 12 months, Incannex Healthcare's shares have ranged in value from as little as $0.041 up to $0.24. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Incannex Healthcare's is 2.088. This would suggest that Incannex Healthcare's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Incannex Healthcare Limited, a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Docklands, Australia.
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Looking for the best performing stocks in Australia? We update this list weekly.
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing Microsoft shares from in Australia.
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Learn about the money market and everyday consumer money market products.
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
Follow these tips to find the best share trading platform for you.
